Rare Biomarkers Specimen Collection and Stabilization

World Market Report

MCP22681

EXECUTIVE ENGAGEMENTS

POOL

906
Number of executives repeatedly engaged by snail & email outreach

INTERACTIONS

181
Interactions with Platform & by Email

PARTICIPANTS

36
Unique # Participated

VALIDATIONS

12
Responses Validated*

COMPANIES

32
Responses Validated*
* Login for a full stack data experience

DATE

APR 2023

TABLES

22

PAGES

88

EDITION

6

PRICE

USD 5600

CODE

MCP22681


COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)

RANK

(S/A/N/T)

%

VALIDATED RESEARCH *

* S = Strong; A = Active; N = Niche; T= Trivial (<1%)
* Login to Participate & View Data Stacks
* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlassTM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.
View All Companies...

PARTICIPATE NOW!
RESEARCH MODULES EXECUTIVES
  

HIGHLIGHTS & REPORT INDEX

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
»Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
»Online interactive peer-to-peer collaborative bespoke updates
»Access to our digital archives and MarketGlass Research Platform
»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China’s already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Rare Biomarkers Specimen Collection and Stabilization Market to Reach $78.6 Billion by 2030
In the changed post COVID-19 business landscape, the global market for Rare Biomarkers Specimen Collection and Stabilization estimated at US$31.6 Billion in the year 2022, is projected to reach a revised size of US$78.6 Billion by 2030, growing at aCAGR of 12.1% over the period 2022-2030. Circulating Cell Free DNA (ccfDNA), one of the segments analyzed in the report, is projected to record 11.2% CAGR and reach US$30.8 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Circulating Tumor Cells (CTCs) segment is readjusted to a revised 12.6% CAGR for the next 8-year period.

The U.S. Market is Estimated at $9.4 Billion, While China is Forecast to Grow at 11.2% CAGR
The Rare Biomarkers Specimen Collection and Stabilization market in the U.S. is estimated at US$9.4 Billion in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$13.3 Billion by the year 2030 trailing a CAGR of 11.2% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 11.1% and 9.9% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 10% CAGR.

SELECT PLAYERS

Advanced Cell Diagnostics, Inc.; Agena Bioscience; ANGLE plc; ApoCell, Inc.; AS One InternationalNTERNATIONAL; BioChain Institute, Inc.; Biolidics Limited; Biomatrica; Bio-Techne Corporation; BioVision, Inc.; Caltag Medsystems Limited; Cytomark Ltd.; DNA Genotek, Inc.; Epic Sciences; EpiGentek Group Inc.; F. Hoffmann-La Roche Ltd; Fluxion Biosciences, Inc.; Geno Technology Inc.; Genomax Technologies Pte Ltd.; GILUPI GmbH; LifeSpan BioSciences, Inc.; MagBio Genomics Inc.; Menarini Silicon Biosystems; MyBioSource.com; Norgen Biotek Corp.; Novus Biologicals, LLC; OraSure Technologies Inc.; Precision for Medicine, Inc.; Promega Corporation; QIAGEN; Rarecells Diagnostics SAS; RareCyte, Inc.; siemens Healthineers; SiO2 Materials Science; STEMCELL Technologies Inc.; Streck, Inc.; Thermo Fisher Scientific, Inc.; Vortex Biosciences; VyCAP B.V.

SEGMENTS

» Product Type (Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles, Circulating Cell Free RNA (ccfRNA) / miRNA) » End-Use (Research, Diagnostics)

GEOGRAPHIES

» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World

TABLE OF CONTENTS

1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Rare Biomarkers Specimen Collection and Stabilization – Global Key Competitors Percentage Market Share in 2022 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
4. GLOBAL MARKET PERSPECTIVE
World Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
World 8-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2023 & 2030
World Recent Past, Current & Future Analysis for Circulating Cell Free DNA (ccfDNA) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
World 8-Year Perspective for Circulating Cell Free DNA (ccfDNA) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
World Recent Past, Current & Future Analysis for Circulating Tumor Cells (CTCs) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
World 8-Year Perspective for Circulating Tumor Cells (CTCs) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
World Recent Past, Current & Future Analysis for Exosomes / Extracellular Vesicles by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
World 8-Year Perspective for Exosomes / Extracellular Vesicles by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
World Recent Past, Current & Future Analysis for Circulating Cell Free RNA (ccfRNA) / miRNA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
World 8-Year Perspective for Circulating Cell Free RNA (ccfRNA) / miRNA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
World Recent Past, Current & Future Analysis for Research by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
World 8-Year Perspective for Research by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
World Recent Past, Current & Future Analysis for Diagnostics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
World 8-Year Perspective for Diagnostics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2023 & 2030
World Rare Biomarkers Specimen Collection and Stabilization Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
UNITED STATES
Rare Biomarkers Specimen Collection and Stabilization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
USA Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
USA 8-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2023 & 2030
USA Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
USA 8-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2023 & 2030
CANADA
Canada Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Canada 8-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2023 & 2030
Canada Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Canada 8-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2023 & 2030
JAPAN
Rare Biomarkers Specimen Collection and Stabilization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
Japan Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Japan 8-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2023 & 2030
Japan Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Japan 8-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2023 & 2030
CHINA
Rare Biomarkers Specimen Collection and Stabilization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
China Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
China 8-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2023 & 2030
China Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
China 8-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2023 & 2030
EUROPE
Rare Biomarkers Specimen Collection and Stabilization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
Europe Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2022 through 2030 and % CAGR
Europe 8-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2023 & 2030
Europe Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Europe 8-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2023 & 2030
Europe Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Europe 8-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2023 & 2030
FRANCE
Rare Biomarkers Specimen Collection and Stabilization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
France Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
France 8-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2023 & 2030
France Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
France 8-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2023 & 2030
GERMANY
Rare Biomarkers Specimen Collection and Stabilization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
Germany Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Germany 8-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2023 & 2030
Germany Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Germany 8-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2023 & 2030
ITALY
Italy Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Italy 8-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2023 & 2030
Italy Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Italy 8-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2023 & 2030
UNITED KINGDOM
Rare Biomarkers Specimen Collection and Stabilization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
UK Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
UK 8-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2023 & 2030
UK Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
UK 8-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2023 & 2030
REST OF EUROPE
Rest of Europe Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Rest of Europe 8-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2023 & 2030
Rest of Europe Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Rest of Europe 8-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2023 & 2030
ASIA-PACIFIC
Rare Biomarkers Specimen Collection and Stabilization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
Asia-Pacific Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Asia-Pacific 8-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2023 & 2030
Asia-Pacific Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Asia-Pacific 8-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2023 & 2030
REST OF WORLD
Rest of World Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Rest of World 8-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by Product Type - Percentage Breakdown of Value Sales for Circulating Cell Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes / Extracellular Vesicles and Circulating Cell Free RNA (ccfRNA) / miRNA for the Years 2023 & 2030
Rest of World Recent Past, Current & Future Analysis for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Research and Diagnostics - Independent Analysis of Annual Sales in US$ Million for the Years 2022 through 2030 and % CAGR
Rest of World 8-Year Perspective for Rare Biomarkers Specimen Collection and Stabilization by End-Use - Percentage Breakdown of Value Sales for Research and Diagnostics for the Years 2023 & 2030

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com